Thyroid transcription factor-1 positive primary breast cancer: a case report with review of the literature by Klingen, Tor A et al.
Klingen et al. Diagnostic Pathology 2010, 5:37
http://www.diagnosticpathology.org/content/5/1/37
Open AccessC A S E  R E P O R TCase ReportThyroid transcription factor-1 positive primary 
breast cancer: a case report with review of the 
literature
Tor A Klingen*1, Ying Chen1, Marian D Gundersen2, Hans Aas3, Bjørn Westre4 and Torill Sauer5
Abstract
This case describes an infiltrating breast tumour with thyroid transcription factor-1 (TTF-1) positive staining and ductal 
differentiation in a 72-year-old woman. The presence of ductal carcinoma in situ with positive TTF-1 is a strong 
indication that this is a primary tumour and not a metastasis from lung.
On PET scan and CT follow up there were no other tumours found in this patient. We are not aware of any previously 
reported TTF-1 positive primary breast carcinoma with ductal differentiation.
Background
TTF-1 is a tissue-specific transcription factor expressed
in epithelial cells of the lung and the thyroid, including C-
cells as well as certain areas of the brain. TTF-1 is
expressed in approximately 72% of pulmonary adenocar-
cinomas[1], and may be a valuable marker for identifying
the lung as the site of origin of a metastatic adenocarci-
noma.
Case Presentation
A 72-year-old gravida 1/para 1 woman presented with a
palpable mass in the left breast.
Her sister died of breast cancer some years earlier.
There was a past history of operated parathyroid ade-
noma some years ago but no previous history of any
malignancy. The patient was a non- smoker and had
never used hormonal drugs.
Clinical examination demonstrated a palpable tumour
in her left breast in the upper inner quadrant, no fixation
to skin or underlying fascia.
Mammography from upper inner quadrant of the left
breast showed a dense, relatively well defined, oval
shaped mass lesion with a microlobulated margin mea-
suring 51 × 33 × 35 mm with coarse calcifications cen-
trally in the mass and in addition finer micro
calcifications antero lateral to the main tumour, malig-
nant in appearance. The total maximal diameter includ-
ing the calcifications was approximately 6 cm.
Ultrasound left breast showed an irregular solid malig-
nant appearing tumour, corresponding to the mammo-
graphic lesion, measuring approximately 38 mm maximal
diameter. No enlarged lymph nodes in the left axillae.
PET scan and CT scan showed no other malignancy
other than known breast tumour.
As no other origin for the tumour was found, the
patient was treated with left mastectomy and sentinel
lymph node mapping. The sentinel node was normal. The
patient had an uncomplicated recovery and was dis-
charged the next day following the operation.
Materials and methods
We performed immunohistochemical investigation using
the indirect streptavidin-biotin method on 3-5 μm slices.
Regarding TTF-1 staining we used same methods at two
different laboratories for verification of the findings. Fur-
ther staining for CK5/6, CK 7, CK20, CK 18, mamma-
globin, GCDFP-15, ER, PGR, chromgranin,
synaptophysin, CD 56, HER 2/neu, Ki67, p 63 and MA
was performed (table 1).
Results
Macroscopic investigation showed a mastectomy speci-
men measuring 21 × 18 × 3 cm, weighing 1042 gram. In
the upper inner quadrant there was a round, well-circum-
scribed tumour with largest diameter 3,8 cm laying 0,6
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Page 2 of 5cm from the chest wall. The tumour was white with pale
yellow necrotic areas (Figure 1).
Microscopic investigation showed a sharp demarcation
of the tumour to the surrounding breast tissue. There was
some necrosis centrally, with more preserved structure
peripherally in the tumour. The tumour tissue grew as
trabeculae and confluent nests with scanty glandular tis-
sue. The tumour cells were large with moderate amount
of cytoplasm. The nuclei were variable in appearance
being round, oval or spindle shaped. The chromatin was
coarsely granulated and vesicular. There were numerous
mitoses and apoptotic bodies (Figure 2).
The nuclei in the invasive tumour cells showed diffuse
and strong positive immunoreactivity to TTF-1 marker
(Figure 3). The neuroendocrine marker CD56 was slightly
positive (Figure 4), whilst chromogranin and synapto-
physin were negative. CK 5/6 was demonstrated in iso-
lated cells within the tumour (Figure 5). Ki67 was positive
in over 50% of the tumour cells. The tumour was positive
for CK7 and CK18 but negative for ER, mammaglobin,
GCDPF-15 and CK20. HER2/neu showed heterogeneous
C-erb-2 protein score 2+/3+, but silver in situ hybridiza-
tion (SISH) without gene amplification. There was a weak
positive reaction to PGR in the biopsy material, but not in
the mastectomy tissue.
An in situ component was seen in the vicinity of the
tumour. The myoepithelial layer of the carcinoma in situ
was verified immunohistochemically with p63 and MA.
The in situ tumour cells had the same morphological
appearance as in the invasive tumour (Figure 6). The in
Table 1: Immunohistochemistry
Antibody Clone Dillution Company
TTF-I SPT24 1:100 Novocastra
CK5/6 D5/16B4 1:800 Chemicon
CK7 OV-TL-12/30 1:100 DAKO
CK20 Ks20.8 Ready to use Roche
CK18 DC10 1:40 DAKO
Mammaglob
in
304-1A5 1:150 DAKO
GCDFP-15 23A3 1:200 Novocastra
ER SP1 Ready to use Roche
PGR 1E2 Ready to use Roche
Chromogran
in
LK2H10 Ready to use Roche
Synaptophys
in
27G12 1:80 Novocastra
CD56 1B6 1:50 Novocastra
Her2/neu 4B5 Ready to use Roche
Ki67 30.9 Ready to use Roche
P63 4A4 Ready to use Roche
MA HUC1-1 Ready to use Roche
Figure 1 Gross specimen showing well-circumscribed deep seat-
ed tumour with yellow necrotic areas.
Figure 2 Tumour with glandular elements, vesicular nuclei and 
mitoses.
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ure 7) and CK5/6 (Figure 8).
Discussion
We believe this case represents TTF-1 positive infiltrat-
ing ductal breast carcinoma, histological grade 3. The
tumour was heterogeneous with small areas of basal-like
and neuroendocrine differentiation.
In three large studies of primary breast carcinomas [1-
3] there were 96, 51 and 35 (total 182) carcinoma cases,
respectively, that were all TTF-1 negative. Only a few
cases of TTF-1 primary small-cell carcinoma in breast
have been reported [4,5]. Yamamoto described two small-
cell breast carcinomas with positive TTF-1 whilst Ersahin
reported one case of small-cell breast carcinoma which
was positive for TTF-1 and basal-like markers. In the case
we report, we found no areas typical for small cell carci-
noma growth, although some areas with trabecular
growth gave a partial neuroendocrine impression.
Because of heterogeneous growth with focally oval and
spindled shaped nuclei, a metaplastic carcinoma was con-
sidered. It is difficult to rule out this alternative, but a lack
of squamous or heterologous metaplasia makes this less
possible.
The initial investigations of the biopsy gave suspicion of
metastasis from lung cancer because of the positive TTF-
1 reaction. Previous studies have shown that lung cancer,
malignant melanoma and lymphoma are the three most
common candidates for secondary breast tumours [6-8].
An almost round tumour could resemble a metastasis,
but some high grade primary tumours can also have this
shape. In our case the tumour was deep seated in the
breast (6 mm from the chest wall). This correlates poorly
with secondary breast tumours which are often found
near to the skin [6,8].
Figure 3 Invasive glandular tumour area is immunoreactive for 
TTF-1.
Figure 4 CD56 immunoreactivity in a focal invasive tumour area.
Figure 5 CK5/6 immunoreactivity demonstrated in isolated cells 
within the invasive tumour.
Figure 6 Ductal carcinoma in situ in vicinity of the tumour.
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Page 4 of 5The presence of a positive TTF-1 reaction in the in situ
component as well as in the invasive component in this
case gives strong support for primary breast carcinoma.
We are not aware of any previously reported TTF-1 posi-
tive ductal carcinoma in situ of non small-cell type. In
order to be quite sure that this represented breast ducts
and not vessels with tumour tissue or peritumoral retrac-
tion artefacts, we also investigated these areas with MA
and p63. Both markers were positive for myoepithelial
cells.
Mammaglobin and GCDFP-15 were negative in the
tumour, but this does not exclude primary breast carci-
noma as these markers have a varied sensitivity of 60-75%
in primary breast carcinomas [9,10].
HER2/neu expression can be seen in both carcinomas
of breast and lung [11]. Our findings with C-erb-2 protein
score 2+/3+ and SISH without gene amplification have no
differential value in this case. We found weak postive
reaction for PGR in the core biopsies. Positive reactions
for both ER and PGR have been reported for lung cancer
[12] and give therefore no support to either breast cancer
or metastasis diagnosis.
In agreement with Ersahin et al we found a positive
expression of the basal-like marker CK5/6. This was espe-
cially noticeable in the in situ component, but only scat-
tered positive cells in the invasive component. This can
possibly represent a dedifferentiation in the tumour tis-
sue. Previous studies have considered ductal carcinoma
in situ with basal- like phenotype as a possible precursor
to invasive basal-like cancer [13,14].
Our case showed high grade ductal carcinoma in situ
and invasive tumour, and such tumours are more com-
monly basal like than low to intermediate grade lesions
[15].
Conclusion
We have presented an unusual case of TTF-1 positive pri-
mary infiltrating ductal carcinoma with focal basal-like
and neuroendocrine differentiation. The in situ compo-
nent with positive TTF-1 is the most important indica-
tion that this represents a primary tumour. Despite the
fact that TTF-1 is known as a specific marker for lung
and thyroid tumours, this case shows that primary non
small-cell breast carcinomas can also be positive.
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Figure 7 Ductal carcinoma in situ with TTF-1 immunoreactivity.
Figure 8 Ductal carcinoma in situ with CK 5/6 immunoreactivity.
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